Treat Mesothelioma Asbestos Cancer
ch_client = "articlealley";
ch_type = "mpu";
ch_width = 675;
ch_height = 250;
ch_color_title = "006699";
ch_color_site_link = '006699';
ch_noborders = 1;
ch_vertical ="premium";
ch_sid = "590x250_Article_New_1st";
var d = document.getElementsByTagName('span');
ch_queries = [];
for(var x = 0; x
Kamis, 28 Juli 2011
The Usefulness of Immunohistochemical Staining in Mesothelioma Research
The Usefulness of Immunohistochemical Staining in Mesothelioma Research
Another interesting study is called, "Immunohistochemical staining for keratin and carcinoembryonic antigen in the diagnosis of malignant Mesothelioma" by Holden, Janet M.D.; Churg, Andrew M.D. - American Journal of Surgical Pathology: April 1984 - Volume 8 - Issue 4. Here is an excerpt: "Abstract - Using formalin-fixed, paraffin-embedded tissue and commercial antisera, we evaluated the usefulness of immunohistochemical staining for carcinoembryonic antigen (CEA) and keratin in the diagnosis of malignant mesothelioma. All 18 adenocarcinomas of lung examined stained for CEA, usually strongly, while only eight of 22 mesotheliomas stained for CEA and the staining was generally weak. Staining for keratin was observed in 10 of 22 mesotheliomas and 12 of 18 adenocarcinomas; there were no differences in intensity of staining between the groups. We conclude that strong diffuse staining for CEA favors a diagnosis of carcinoma, and negative staining for CEA is against a diagnosis of carcinoma, but these are relative and not absolute criteria. We find that staining for keratin is of no use in distinguishing these types of tumors."
Another interesting study is called, "Extrapleural pneumonectomy, chemotherapy, and radiotherapy in the treatment of diffuse malignant pleural Mesothelioma" - The Journal of Thoracic and Cardiovascular Surgery, Vol 102, 10-14, 1991 - DJ Sugarbaker, EC Heher, TH Lee, G Couper, S Mentzer, JM Corson, JJ Collins Jr, R Shemin, R Pugatch and L Weissman - Division of Thoracic Surgery, Brigham & Women's Hospital, Boston, MA 02115.  Here is an excerpt: "Malignant pleural mesothelioma has been considered a uniformly fatal disease associated with a median survival of 4 to 18 months. Extrapleural pneumonectomy alone has proved disappointing in the treatment of this disease, as have chemotherapy and radiotherapy. From 1980 to 1990, 31 patients with pleural mesothelioma underwent multimodality therapy that included extrapleural pneumonectomy with resection of the pericardium and diaphragm. The age of the patients was 53.4 +/- 8.6 years; 26 were male. All patients had the pathologic diagnosis reviewed before treatment. At thoracotomy six patients had residual (unresectable) gross disease, and in 23 there was histologic evidence of disease at the resection margin. The perioperative morbidity and mortality rates were 19% and 6%, respectively. The mean length of hospital stay for the 29 patients who survived the operation was 10.9 +/- 3.5 days. Postoperatively 26 patients received cyclophosphamide, doxorubicin, and cis-platinum chemotherapy with or without radiotherapy. The survival rates were 70% at 1 year and 48% at 2 years. Trends toward improved survival in the patients with complete resections approached but did not reach statistical significance. These data suggest that this multimodality protocol can be administered with acceptable morbidity and mortality. Prospective trials are justified to further clarify the role of this approach."
An interesting study is called, "HBME-1, MOC-31, WT1 and calretinin: an assessment of recently described markers for mesothelioma and adenocarcinoma" by Oates, Edwards - Histopathology - Volume 36, Issue 4, pages 341–347, April 2000. Here is an excerpt: "Methods and results- Paraffin-embedded formalin-fixed blocks from six reactive pleuras, 42 mesotheliomas and 40 adenocarcinomas were used. Sections were stained for Leu-M1, HBME-1, calretinin, WT1 and MOC-31. Leu-M1 was positive or equivocal in 34% of mesotheliomas and in 78% of adenocarcinomas; reactive pleuras were all negative. HBME-1 was positive or equivocal in 76% of mesotheliomas and in 73% of adenocarcinomas; five reactive pleuras were positive. Calretinin was positive or equivocal in 92% of mesotheliomas and in 73% of adenocarcinomas; two reactive pleura were equivocal and four were positive. WT1 was positive or equivocal in 72% of mesotheliomas (excluding autopsy cases) and in 20% of adenocarcinomas; all reactive pleuras were positive. MOC-31 was positive or equivocal in 5% of mesotheliomas and in 90% of adenocarcinomas; all reactive pleuras were negative. The reaction with Leu-M1 was graded as equivocal in 25% of the adenocarcinomas. All 24 of the autopsy cases of mesothelioma were negative for WT1 and in many operative specimens only the periphery was stained. Conclusions - Neither calretinin nor HBME-1 are sufficiently discriminatory to be of use, even as members of a panel of antibodies. WT1 shows some promise, but it cannot be used on autopsy material. The utility of MOC-31 is confirmed, and outperforms Leu-M1."
We all owe a debt of gratitude to these fine researchers. If you found any of these excerpts interesting, please read the studies in their entirety.
Another interesting study is called, "Immunohistochemical staining for keratin and carcinoembryonic antigen in the diagnosis of malignant Mesothelioma" by Holden, Janet M.D.; Churg, Andrew M.D. - American Journal of Surgical Pathology: April 1984 - Volume 8 - Issue 4. Here is an excerpt: "Abstract - Using formalin-fixed, paraffin-embedded tissue and commercial antisera, we evaluated the usefulness of immunohistochemical staining for carcinoembryonic antigen (CEA) and keratin in the diagnosis of malignant mesothelioma. All 18 adenocarcinomas of lung examined stained for CEA, usually strongly, while only eight of 22 mesotheliomas stained for CEA and the staining was generally weak. Staining for keratin was observed in 10 of 22 mesotheliomas and 12 of 18 adenocarcinomas; there were no differences in intensity of staining between the groups. We conclude that strong diffuse staining for CEA favors a diagnosis of carcinoma, and negative staining for CEA is against a diagnosis of carcinoma, but these are relative and not absolute criteria. We find that staining for keratin is of no use in distinguishing these types of tumors."
Another interesting study is called, "Extrapleural pneumonectomy, chemotherapy, and radiotherapy in the treatment of diffuse malignant pleural Mesothelioma" - The Journal of Thoracic and Cardiovascular Surgery, Vol 102, 10-14, 1991 - DJ Sugarbaker, EC Heher, TH Lee, G Couper, S Mentzer, JM Corson, JJ Collins Jr, R Shemin, R Pugatch and L Weissman - Division of Thoracic Surgery, Brigham & Women's Hospital, Boston, MA 02115.  Here is an excerpt: "Malignant pleural mesothelioma has been considered a uniformly fatal disease associated with a median survival of 4 to 18 months. Extrapleural pneumonectomy alone has proved disappointing in the treatment of this disease, as have chemotherapy and radiotherapy. From 1980 to 1990, 31 patients with pleural mesothelioma underwent multimodality therapy that included extrapleural pneumonectomy with resection of the pericardium and diaphragm. The age of the patients was 53.4 +/- 8.6 years; 26 were male. All patients had the pathologic diagnosis reviewed before treatment. At thoracotomy six patients had residual (unresectable) gross disease, and in 23 there was histologic evidence of disease at the resection margin. The perioperative morbidity and mortality rates were 19% and 6%, respectively. The mean length of hospital stay for the 29 patients who survived the operation was 10.9 +/- 3.5 days. Postoperatively 26 patients received cyclophosphamide, doxorubicin, and cis-platinum chemotherapy with or without radiotherapy. The survival rates were 70% at 1 year and 48% at 2 years. Trends toward improved survival in the patients with complete resections approached but did not reach statistical significance. These data suggest that this multimodality protocol can be administered with acceptable morbidity and mortality. Prospective trials are justified to further clarify the role of this approach."
An interesting study is called, "HBME-1, MOC-31, WT1 and calretinin: an assessment of recently described markers for mesothelioma and adenocarcinoma" by Oates, Edwards - Histopathology - Volume 36, Issue 4, pages 341–347, April 2000. Here is an excerpt: "Methods and results- Paraffin-embedded formalin-fixed blocks from six reactive pleuras, 42 mesotheliomas and 40 adenocarcinomas were used. Sections were stained for Leu-M1, HBME-1, calretinin, WT1 and MOC-31. Leu-M1 was positive or equivocal in 34% of mesotheliomas and in 78% of adenocarcinomas; reactive pleuras were all negative. HBME-1 was positive or equivocal in 76% of mesotheliomas and in 73% of adenocarcinomas; five reactive pleuras were positive. Calretinin was positive or equivocal in 92% of mesotheliomas and in 73% of adenocarcinomas; two reactive pleura were equivocal and four were positive. WT1 was positive or equivocal in 72% of mesotheliomas (excluding autopsy cases) and in 20% of adenocarcinomas; all reactive pleuras were positive. MOC-31 was positive or equivocal in 5% of mesotheliomas and in 90% of adenocarcinomas; all reactive pleuras were negative. The reaction with Leu-M1 was graded as equivocal in 25% of the adenocarcinomas. All 24 of the autopsy cases of mesothelioma were negative for WT1 and in many operative specimens only the periphery was stained. Conclusions - Neither calretinin nor HBME-1 are sufficiently discriminatory to be of use, even as members of a panel of antibodies. WT1 shows some promise, but it cannot be used on autopsy material. The utility of MOC-31 is confirmed, and outperforms Leu-M1."
We all owe a debt of gratitude to these fine researchers. If you found any of these excerpts interesting, please read the studies in their entirety.
Pulmonary Toxicity and Malignant Mesotheliomas
Pulmonary Toxicity and Malignant Mesotheliomas
Another interesting study is called, "Potential Role of Histone Deacetylase Inhibitors in Mesothelioma: Clinical Experience with Suberoylanilide Hydroxamic Acid Clinical Lung Cancer" - Chest Surg Clin N Am. 1994 Feb;4(1):113-26 - Allen KB, Faber LP, Warren WH. Here is an excerpt: "Abstract - Diffuse malignant pleural mesothelioma is an uncommon, uniformly fatal malignancy. Controversy continues to surround the optimal surgical procedure, both extrapleural pneumonectomy or pleurectomy, which should be utilized in conjunction with post-operative chemotherapy and/or radiotherapy. This retrospective study reviews a single institution's experience with extrapleural pneumonectomy and pleurectomy in the multimodality treatment of diffuse malignant pleural mesothelioma.
Another interesting study is called, "Phase II trial of mitomycin in malignant mesothelioma." By Bajorin, D, Kelsen, D, Mintzer, DM - CANCER TREAT. REP. Vol. 71, no. 9, pp. 857-858. 1987. Here is an excerpt: "Malignant mesothelioma is a highly lethal neoplasm. Recent data noted in vivo antineoplastic effects of a combination of mitomycin and cisplatin (DDP) greater than either agent alone in human tumor xenograft mesothelioma. While DDP singly has some efficacy, mitomycin has not been systematically evaluated in this disease. A phase II trial was therefore conducted to determine the activity of mitomycin in malignant mesothelioma. Pulmonary toxicity was substantial. Two responding patients developed dyspnea and hypoxemia occurring at cumulative doses of 40 and 50 mg/m super(2), respectively. One patient had a transbronchial biopsy consistent with drug-induced pulmonary fibrosis and never achieved resolution of hypoxemia with corticosteroid therapy prior to death from progressive mesothelioma. The second patient responded to corticosteroid therapy with resolution of dyspnea and hypoxemia but relapsed after discontinuing mitomycin."
Another interesting study is called, "Immunohistological staining of reactive mesothelium, mesothelioma, and lung carcinoma with a panel of monoclonal antibodies." - J Clin Pathol 1987;40:19-25 by A K Ghosh, K C Gatter, M S Dunnill, D Y Mason. Here is an excerpt: "Abstract - A panel of seven monoclonal antiepithelial antibodies of different specificities, including anticytokeratin, human milk fat globule membrane, C, and carcinoembryonic antigen (CEA) were used with the alkaline phosphatase-antialkaline phosphatase (APAAP) immunostaining technique to determine their value in the differentiation between benign and malignant mesothelial cells and lung carcinoma in histological preparations. The anticytokeratin antibody reacted strongly with all cases of reactive mesothelium, mesothelioma, and lung carcinoma. Antibodies to human milk fat globule membrane and the Ca antigen stained mesothelioma and carcinoma and 43% of cases of reactive mesothelium. Staining for carcinoembryonic antigen was not detected in reactive mesothelium or mesothelioma, but was present in most of the lung carcinomas. CEA seemed to be the single most useful marker in distinguishing carcinoma from mesothelioma in that a positive reaction for CEA would indicate carcinoma rather than mesothelioma."
Another interesting study is called, "Podoplanin as a marker for Mesothelioma" by Noriko Kimura, Itaru Kimura - Pathology International - Volume 55, Issue 2, pages 83–86, February 2005. Here is an excerpt: "Podoplanin is a specific marker for lymph vessel endothelial cells. It was noted that podoplanin is expressed in reactive mesothelial cells. The utility of podoplanin for the histological diagnosis of tumors was then investigated, especially for mesothelioma. Immunohistochemical study of podoplanin was carried out in five malignant mesotheliomas and 118 other tumors including 93 adenocarcinomas, four squamous cell carcinomas, six gastrointestinal stromal tumors and five endocrine tumors. Immunoreactivity for podoplanin was demonstrated on the cell membrane of tumor cells for all mesotheliomas. All other tumors were negative for podoplanin. Among the many antibodies used for differential diagnosis of malignant mesothelioma, podoplanin has the potential to be an excellent tumor marker in both specificity and sensitivity. The utility of podoplanin as a marker for mesothelioma will be confirmed by further studies."
We all owe a debt of gratitude to these fine researchers. If you found any of these excerpts interesting, please read the studies in their entirety.
Another interesting study is called, "Potential Role of Histone Deacetylase Inhibitors in Mesothelioma: Clinical Experience with Suberoylanilide Hydroxamic Acid Clinical Lung Cancer" - Chest Surg Clin N Am. 1994 Feb;4(1):113-26 - Allen KB, Faber LP, Warren WH. Here is an excerpt: "Abstract - Diffuse malignant pleural mesothelioma is an uncommon, uniformly fatal malignancy. Controversy continues to surround the optimal surgical procedure, both extrapleural pneumonectomy or pleurectomy, which should be utilized in conjunction with post-operative chemotherapy and/or radiotherapy. This retrospective study reviews a single institution's experience with extrapleural pneumonectomy and pleurectomy in the multimodality treatment of diffuse malignant pleural mesothelioma.
Another interesting study is called, "Phase II trial of mitomycin in malignant mesothelioma." By Bajorin, D, Kelsen, D, Mintzer, DM - CANCER TREAT. REP. Vol. 71, no. 9, pp. 857-858. 1987. Here is an excerpt: "Malignant mesothelioma is a highly lethal neoplasm. Recent data noted in vivo antineoplastic effects of a combination of mitomycin and cisplatin (DDP) greater than either agent alone in human tumor xenograft mesothelioma. While DDP singly has some efficacy, mitomycin has not been systematically evaluated in this disease. A phase II trial was therefore conducted to determine the activity of mitomycin in malignant mesothelioma. Pulmonary toxicity was substantial. Two responding patients developed dyspnea and hypoxemia occurring at cumulative doses of 40 and 50 mg/m super(2), respectively. One patient had a transbronchial biopsy consistent with drug-induced pulmonary fibrosis and never achieved resolution of hypoxemia with corticosteroid therapy prior to death from progressive mesothelioma. The second patient responded to corticosteroid therapy with resolution of dyspnea and hypoxemia but relapsed after discontinuing mitomycin."
Another interesting study is called, "Immunohistological staining of reactive mesothelium, mesothelioma, and lung carcinoma with a panel of monoclonal antibodies." - J Clin Pathol 1987;40:19-25 by A K Ghosh, K C Gatter, M S Dunnill, D Y Mason. Here is an excerpt: "Abstract - A panel of seven monoclonal antiepithelial antibodies of different specificities, including anticytokeratin, human milk fat globule membrane, C, and carcinoembryonic antigen (CEA) were used with the alkaline phosphatase-antialkaline phosphatase (APAAP) immunostaining technique to determine their value in the differentiation between benign and malignant mesothelial cells and lung carcinoma in histological preparations. The anticytokeratin antibody reacted strongly with all cases of reactive mesothelium, mesothelioma, and lung carcinoma. Antibodies to human milk fat globule membrane and the Ca antigen stained mesothelioma and carcinoma and 43% of cases of reactive mesothelium. Staining for carcinoembryonic antigen was not detected in reactive mesothelium or mesothelioma, but was present in most of the lung carcinomas. CEA seemed to be the single most useful marker in distinguishing carcinoma from mesothelioma in that a positive reaction for CEA would indicate carcinoma rather than mesothelioma."
Another interesting study is called, "Podoplanin as a marker for Mesothelioma" by Noriko Kimura, Itaru Kimura - Pathology International - Volume 55, Issue 2, pages 83–86, February 2005. Here is an excerpt: "Podoplanin is a specific marker for lymph vessel endothelial cells. It was noted that podoplanin is expressed in reactive mesothelial cells. The utility of podoplanin for the histological diagnosis of tumors was then investigated, especially for mesothelioma. Immunohistochemical study of podoplanin was carried out in five malignant mesotheliomas and 118 other tumors including 93 adenocarcinomas, four squamous cell carcinomas, six gastrointestinal stromal tumors and five endocrine tumors. Immunoreactivity for podoplanin was demonstrated on the cell membrane of tumor cells for all mesotheliomas. All other tumors were negative for podoplanin. Among the many antibodies used for differential diagnosis of malignant mesothelioma, podoplanin has the potential to be an excellent tumor marker in both specificity and sensitivity. The utility of podoplanin as a marker for mesothelioma will be confirmed by further studies."
We all owe a debt of gratitude to these fine researchers. If you found any of these excerpts interesting, please read the studies in their entirety.
Perfect Data connected to Diffuse Pleural Malignant Mesothelioma
Perfect Data connected to Diffuse Pleural Malignant Mesothelioma
One of the most characters of this pleural mesothelioma is a a result of one being bare freely to asbestos. Most of the time it is categorized under pleural mesothelioma which is a malignant tumor on the outward component of the lungs. The pleura is a slim membrane that shrouds the lungs. When it is lessened, it will result to transparent symptoms to the subject individual.
Experiencing this kind of a cancerous disease cannot be identified right away because the symptoms can be projected even 20 years after he inhaled asbestos
One of the most characters of this pleural mesothelioma is a a result of one being bare freely to asbestos. Most of the time it is categorized under pleural mesothelioma which is a malignant tumor on the outward component of the lungs. The pleura is a slim membrane that shrouds the lungs. When it is lessened, it will result to transparent symptoms to the subject individual.
Experiencing this kind of a cancerous disease cannot be identified right away because the symptoms can be projected even 20 years after he inhaled asbestos
Mesothelioma Treatment and Aggressive Debulking
Mesothelioma Treatment and Aggressive Debulking
ch_client = "articlealley";
ch_type = "mpu";
ch_width = 675;
ch_height = 250;
ch_color_title = "006699";
ch_color_site_link = '006699';
ch_noborders = 1;
ch_vertical ="premium";
ch_sid = "590x250_Article_New_1st";
var d = document.getElementsByTagName('span');
ch_queries = [];
for(var x = 0; x
ch_client = "articlealley";
ch_type = "mpu";
ch_width = 675;
ch_height = 250;
ch_color_title = "006699";
ch_color_site_link = '006699';
ch_noborders = 1;
ch_vertical ="premium";
ch_sid = "590x250_Article_New_1st";
var d = document.getElementsByTagName('span');
ch_queries = [];
for(var x = 0; x
Mesothelioma Research Limitations and Computed Tomography
Mesothelioma Research Limitations and Computed Tomography
Another interesting study is called, “Effect of drug-light interval on photodynamic therapy with meta-tetrahydroxyphenylchlorin in malignant Mesothelioma” by Hans-Beat Ris, Hans Jörg Altermatt, Bernhard Nachbur, J. Charles M. Stewart, Qiang Wang, Chang Kee Lim, Raymond Bonnett, Ulrich Althaus - International Journal of Cancer Volume 53, Issue 1, pages 141–146, 2 January 1993. Here is an excerpt: “Abstract - The influence of the time interval (TI) between drug administration and laser activation on selectivity of meta-tetrahydroxy- phenylchlorin(mTHPC)-mediated photodynamic therapy (PDT) for tumour tissue was assessed in BALB/c nude mice bearing human malignant mesothelioma xenografts. Following i.p. administration of 0.3 mg/kg mTHPC, a light dose of 10 J/cm2 and 0.1 W/cm2 was delivered at 650 nm on the tumour and an equal-sized area of the hind leg after 4. I2, 24 and 36 hr and 2,3, 4,5 and 6 days to groups of 6 animals (surface irradiance). Then, 72 hr after light delivery, the depth of necrosis was measured in the tumour and in the skin and underlying muscle of the hind leg. Photosensitized necrosis occurred in normal tissue at TI from 4 hr to 3 days and in the tumour at TI from I2 hr to 4 days. The therapeutic ratio of mTHPC-PDT varied significantly with the time interval between drug administration and laser activation and was greatest at an interval of 3 days. mTHPC concentration was measured in 3 control unirradiated animals at all time points in normal tissues and in tumour tissue, and found to be the same in both tissues. Thus the tissue concentration of mTHPC was of limited use as regards the prediction of photosen-sitizing effects in the tumour model.”
One interesting study is called, “The Journal of Thoracic and Cardiovascular Surgery” - Vol 96, 171-177, - 1988 by The American Association for Thoracic Surgery and The Western Thoracic Surgical Association. Here is an excerpt: “The role of computed tomography scanning in the initial assessment and the follow-up of malignant pleural Mesothelioma” by VW Rusch, JD Godwin and WP Shuman - Department of Surgery, University of Washington, Seattle 98195. Here is an excerpt: “Between October 1983 and April 1987, 20 patients with malignant mesothelioma underwent computed tomography scans of the chest and upper abdomen to evaluate the extent of disease before treatment. Twelve of these 20 patients deemed to have some potential for long-term survival had scans performed every 3 months after operation to help detect recurrent disease. Anatomic correlation of computed tomography scan findings was available in all 20 patients. The limitations of computed tomography in initial evaluation were its difficulties in assessing (1) chest wall involvement (nine patients), (2) mediastinal lymph nodes (four patients), (3) transdiaphragmatic extension of tumor (four patients), and (4) peritoneal studding and solid organ metastases less than 2 mm in size (one patient). Computed tomography was helpful in detecting recurrent disease in the 12 patients having long-term follow- up. In six of eight cases with histologically proved recurrence, computed tomography detected tumors from 1 to 8 months before the onset of signs or symptoms. Although computed tomography is known to provide far more information about the extent of disease than plain radiographs, it remains an imperfect tool for the staging of disease in patients with malignant mesothelioma. Despite its limitations, computed tomography is probably the most accurate way to provide follow-up for patients during treatment.” Eur J Respir Dis. 1984 Apr;65(3):162-8.
Another interesting study is called, “Malignant mesothelioma of the pleura: clinical aspects and symptomatic treatment.” By Law MR, Hodson ME, Turner-Warwick M. Here is an excerpt: “Abstract - A series of 140 patients with malignant pleural mesothelioma is reported. Clinical presentation was delayed in cases without a large effusion, but there was extensive tumour at presentation, shown by thoracoscopy, thoracotomy or computed tomography, in all patients investigated. Thoracoscopy was a useful diagnostic alternative to thoracotomy. With progression of disease, mesothelial extension was more important than distant metastases, which were usually too small and sparse to produce symptoms. Skin deposits of tumour in sites of previous invasive procedures did not cause pain or other clinical problems, and we consider that diagnostic and therapeutic procedures should not be withheld to avoid them. In the management of recurrent pleural effusions, intrapleural bleomycin, preceded by aspiration and followed by suction, was a useful alternative to surgery. Pneumothorax, spontaneous or iatrogenic, required decortication. Adequate pain relief was difficult; radiotherapy and nerve blocking procedures were not effective and opiates were often necessary.”
We all owe a debt of gratitude to these fine researchers. If you found any of these excerpts interesting, please read the studies in their entirety.
Monty Wrobleski is the author of this article. For more information please click on the following links
Mesothelioma Attorney
Mesothelioma Lawyer
Mesothelioma Lawyer
Another interesting study is called, “Effect of drug-light interval on photodynamic therapy with meta-tetrahydroxyphenylchlorin in malignant Mesothelioma” by Hans-Beat Ris, Hans Jörg Altermatt, Bernhard Nachbur, J. Charles M. Stewart, Qiang Wang, Chang Kee Lim, Raymond Bonnett, Ulrich Althaus - International Journal of Cancer Volume 53, Issue 1, pages 141–146, 2 January 1993. Here is an excerpt: “Abstract - The influence of the time interval (TI) between drug administration and laser activation on selectivity of meta-tetrahydroxy- phenylchlorin(mTHPC)-mediated photodynamic therapy (PDT) for tumour tissue was assessed in BALB/c nude mice bearing human malignant mesothelioma xenografts. Following i.p. administration of 0.3 mg/kg mTHPC, a light dose of 10 J/cm2 and 0.1 W/cm2 was delivered at 650 nm on the tumour and an equal-sized area of the hind leg after 4. I2, 24 and 36 hr and 2,3, 4,5 and 6 days to groups of 6 animals (surface irradiance). Then, 72 hr after light delivery, the depth of necrosis was measured in the tumour and in the skin and underlying muscle of the hind leg. Photosensitized necrosis occurred in normal tissue at TI from 4 hr to 3 days and in the tumour at TI from I2 hr to 4 days. The therapeutic ratio of mTHPC-PDT varied significantly with the time interval between drug administration and laser activation and was greatest at an interval of 3 days. mTHPC concentration was measured in 3 control unirradiated animals at all time points in normal tissues and in tumour tissue, and found to be the same in both tissues. Thus the tissue concentration of mTHPC was of limited use as regards the prediction of photosen-sitizing effects in the tumour model.”
One interesting study is called, “The Journal of Thoracic and Cardiovascular Surgery” - Vol 96, 171-177, - 1988 by The American Association for Thoracic Surgery and The Western Thoracic Surgical Association. Here is an excerpt: “The role of computed tomography scanning in the initial assessment and the follow-up of malignant pleural Mesothelioma” by VW Rusch, JD Godwin and WP Shuman - Department of Surgery, University of Washington, Seattle 98195. Here is an excerpt: “Between October 1983 and April 1987, 20 patients with malignant mesothelioma underwent computed tomography scans of the chest and upper abdomen to evaluate the extent of disease before treatment. Twelve of these 20 patients deemed to have some potential for long-term survival had scans performed every 3 months after operation to help detect recurrent disease. Anatomic correlation of computed tomography scan findings was available in all 20 patients. The limitations of computed tomography in initial evaluation were its difficulties in assessing (1) chest wall involvement (nine patients), (2) mediastinal lymph nodes (four patients), (3) transdiaphragmatic extension of tumor (four patients), and (4) peritoneal studding and solid organ metastases less than 2 mm in size (one patient). Computed tomography was helpful in detecting recurrent disease in the 12 patients having long-term follow- up. In six of eight cases with histologically proved recurrence, computed tomography detected tumors from 1 to 8 months before the onset of signs or symptoms. Although computed tomography is known to provide far more information about the extent of disease than plain radiographs, it remains an imperfect tool for the staging of disease in patients with malignant mesothelioma. Despite its limitations, computed tomography is probably the most accurate way to provide follow-up for patients during treatment.” Eur J Respir Dis. 1984 Apr;65(3):162-8.
Another interesting study is called, “Malignant mesothelioma of the pleura: clinical aspects and symptomatic treatment.” By Law MR, Hodson ME, Turner-Warwick M. Here is an excerpt: “Abstract - A series of 140 patients with malignant pleural mesothelioma is reported. Clinical presentation was delayed in cases without a large effusion, but there was extensive tumour at presentation, shown by thoracoscopy, thoracotomy or computed tomography, in all patients investigated. Thoracoscopy was a useful diagnostic alternative to thoracotomy. With progression of disease, mesothelial extension was more important than distant metastases, which were usually too small and sparse to produce symptoms. Skin deposits of tumour in sites of previous invasive procedures did not cause pain or other clinical problems, and we consider that diagnostic and therapeutic procedures should not be withheld to avoid them. In the management of recurrent pleural effusions, intrapleural bleomycin, preceded by aspiration and followed by suction, was a useful alternative to surgery. Pneumothorax, spontaneous or iatrogenic, required decortication. Adequate pain relief was difficult; radiotherapy and nerve blocking procedures were not effective and opiates were often necessary.”
We all owe a debt of gratitude to these fine researchers. If you found any of these excerpts interesting, please read the studies in their entirety.
Monty Wrobleski is the author of this article. For more information please click on the following links
Mesothelioma Attorney
Mesothelioma Lawyer
Mesothelioma Lawyer
Mesothelioma Historty, Lawsuits and Lawyers
Mesothelioma Historty, Lawsuits and Lawyers
Mesothelioma staging systems define mesothelioma stages; however, they are far more descriptive for pleural mesothelioma than for peritoneal mesothelioma. These systems have changed over time. Mesothelioma stages are important considerations in treatment and prognosis. By sectioning a progressive disease into stages, doctors can evaluate mesothelioma treatment options. Grouping similar variables for evaluation is beneficial to developing mesothelioma treatment options for different mesothelioma stages.
Mesothelioma cancer
In 1976 the Butchart staging system identified four mesothelioma stages for diffuse pleural malignant mesothelioma by location. At stage one, the tumor is in one side of the pleural lining. At stage two, the tumor is malignant and has entered both lungs, and has the potential to spread. In stage three, the tumor has entered the peritoneum (abdomen region), and at stage four, the cancer has spread through the blood stream.
In the 1980s Chahinian added detailed tumor stages, lymph node stages and metastases stages to the pleural mesothelioma staging system. This staging system is referred to as TNM and is used within elaborative staging systems. In 1990 the UICC (Union Internationale Contre le Cancer) expounded on Chahinian's mesothelioma stages. The Butchart mesothelioma staging system in its originality is obsolete for mesothelioma life expectancy statistics, however other mesothelioma stages have been developed from it, and many cancer institutions modify it for their evaluative purposes.
The IMIG (International Mesothelioma Interest Group) in a 1995 Journal of Chest from the American College of Chest Physicians proposed international acceptance for a detailed universal staging system. This staging system demands precise tumor location, and is based on TNM and the International Lung Cancer Staging System.
Mesothelioma Lawsuits
Mesothelioma can be intimidating and frightening diagnosis to receive, especially if the mesothelioma is connected with occupational asbestos exposure, particularly mesothelioma may not even appear in an individual until many years or even decades after the initial asbestos exposure. In order to properly deal with this condition, it is important to address the medical treatment of the mesothelioma first. The prospect of a mesothelioma lawsuit can seem intimidating in and of itself, therefore this article is intended to assuage any fears about mesothelioma litigation by provide answers to questions commonly asked about mesothelioma lawsuits.
Mesothelioma Lawyer
Once a treatment course has been determined and initiated, the next best step may be to inquire with a qualified mesothelioma lawyer about the possibility of mesothelioma litigation. If your case goes to trial, expect your lawyer to consult with other experts, a trial preparation specialist, multimedia experts who can help present the evidence at trial in the most convincing manner, and witnesses who can bolster your own testimony in your mesothelioma trial. In an effort to avoid the cost
Author Bio
Sarah Adams is a freelance writer specialized in writing SEO contents for many companies including www.mesotheliomacenters.com/
Mesothelioma staging systems define mesothelioma stages; however, they are far more descriptive for pleural mesothelioma than for peritoneal mesothelioma. These systems have changed over time. Mesothelioma stages are important considerations in treatment and prognosis. By sectioning a progressive disease into stages, doctors can evaluate mesothelioma treatment options. Grouping similar variables for evaluation is beneficial to developing mesothelioma treatment options for different mesothelioma stages.
Mesothelioma cancer
In 1976 the Butchart staging system identified four mesothelioma stages for diffuse pleural malignant mesothelioma by location. At stage one, the tumor is in one side of the pleural lining. At stage two, the tumor is malignant and has entered both lungs, and has the potential to spread. In stage three, the tumor has entered the peritoneum (abdomen region), and at stage four, the cancer has spread through the blood stream.
In the 1980s Chahinian added detailed tumor stages, lymph node stages and metastases stages to the pleural mesothelioma staging system. This staging system is referred to as TNM and is used within elaborative staging systems. In 1990 the UICC (Union Internationale Contre le Cancer) expounded on Chahinian's mesothelioma stages. The Butchart mesothelioma staging system in its originality is obsolete for mesothelioma life expectancy statistics, however other mesothelioma stages have been developed from it, and many cancer institutions modify it for their evaluative purposes.
The IMIG (International Mesothelioma Interest Group) in a 1995 Journal of Chest from the American College of Chest Physicians proposed international acceptance for a detailed universal staging system. This staging system demands precise tumor location, and is based on TNM and the International Lung Cancer Staging System.
Mesothelioma Lawsuits
Mesothelioma can be intimidating and frightening diagnosis to receive, especially if the mesothelioma is connected with occupational asbestos exposure, particularly mesothelioma may not even appear in an individual until many years or even decades after the initial asbestos exposure. In order to properly deal with this condition, it is important to address the medical treatment of the mesothelioma first. The prospect of a mesothelioma lawsuit can seem intimidating in and of itself, therefore this article is intended to assuage any fears about mesothelioma litigation by provide answers to questions commonly asked about mesothelioma lawsuits.
Mesothelioma Lawyer
Once a treatment course has been determined and initiated, the next best step may be to inquire with a qualified mesothelioma lawyer about the possibility of mesothelioma litigation. If your case goes to trial, expect your lawyer to consult with other experts, a trial preparation specialist, multimedia experts who can help present the evidence at trial in the most convincing manner, and witnesses who can bolster your own testimony in your mesothelioma trial. In an effort to avoid the cost
Author Bio
Sarah Adams is a freelance writer specialized in writing SEO contents for many companies including www.mesotheliomacenters.com/
Mesothelioma Chemotherapy-What are your options
Mesothelioma Chemotherapy-What are your options
Chemotherapy generally means the use of drugs to treat diseases and ailments, but the term is used more commonly to describe the use of anticancer drugs. These drugs treat cancer by killing the cancerous cells.
Anti cancer drugs work by specifically targeting certain processes in cancerous cells to stop cell division and multiplication ultimately leading to the death of the cancerous cells. These drugs are however not highly specific in their mode of action and in addition to killing cancerous cells, anti cancer drugs also kill normal healthy cells such as those involved in hair growth.
There are several options for chemotherapy of mesothelioma cancer. Most of these drugs have side effects like nausea, vomiting, loss of hair, loss of appetite and decreased immunity which makes them more susceptible to infections. Any symptoms experienced while undergoing treatment with chemotherapeutic drugs should be reported to the doctor.
Many patients will consider chemotherapy as a treatment option. Understanding the various chemotherapy options and available treatments often helps patients and their loved ones make the best decision for their personal situation. Evaluating Chemotherapy Options Deciding the best chemotherapy option for treating specific mesothelioma cases depends on a number of factors, including the type of mesothelioma, the stage of the disease, and other treatment being used by the victim. Factors such as overall physical health and age are also taken into consideration when planning a chemotherapy treatment plan.
Currently more than 100 chemotherapy drugs are on the market but only a handful have proven to be appropriate for fighting mesothelioma. In most cases, doctors treating mesothelioma patients recommend combination therapy - the tandem use of two different chemotherapy drugs. These combination's have been proven to be the most successful in treating the cancer.
All treatment options will be thoroughly discussed with the patient's oncologistspecialist cancer doctor before a decision is made. Patients should provide a full disclosure of their medical history, including details of any prescriptions and over-the-counter medications being taken to ensure treatment is administered with the most appropriate chemotherapeutic agent.
Currently, the most common chemotherapy drugs for mesothelioma include Alimta (the only FDA-approved drug specifically designed for the treatment of mesothelioma), Cisplatin, Carboplatin, Onconase, Gemcitabine, and Navelbine. The medications are usually administered conventionally (by IV or pill form), or may be used in a newer treatment method called heated chemotherapy.
Can Chemotherapy Cure Mesothelioma?
No it can not cure the cancer, currently there is no proven cure for mesothelioma. However, chemotherapy can help control symptoms and shrink tumors and is largely used as a palliative measure to help improve the patient's quality of life. The development of combination treatments has proved successful in achieving longer survival rates and researchers continue to look for new ways to fight this terrible disease.
Bello Kamorudeen is an health worker and author of several mesothelioma articles.For more inforation on mesothelioma treatments visit http://www.mesotheliomacorner.blospot.com
Chemotherapy generally means the use of drugs to treat diseases and ailments, but the term is used more commonly to describe the use of anticancer drugs. These drugs treat cancer by killing the cancerous cells.
Anti cancer drugs work by specifically targeting certain processes in cancerous cells to stop cell division and multiplication ultimately leading to the death of the cancerous cells. These drugs are however not highly specific in their mode of action and in addition to killing cancerous cells, anti cancer drugs also kill normal healthy cells such as those involved in hair growth.
There are several options for chemotherapy of mesothelioma cancer. Most of these drugs have side effects like nausea, vomiting, loss of hair, loss of appetite and decreased immunity which makes them more susceptible to infections. Any symptoms experienced while undergoing treatment with chemotherapeutic drugs should be reported to the doctor.
Many patients will consider chemotherapy as a treatment option. Understanding the various chemotherapy options and available treatments often helps patients and their loved ones make the best decision for their personal situation. Evaluating Chemotherapy Options Deciding the best chemotherapy option for treating specific mesothelioma cases depends on a number of factors, including the type of mesothelioma, the stage of the disease, and other treatment being used by the victim. Factors such as overall physical health and age are also taken into consideration when planning a chemotherapy treatment plan.
Currently more than 100 chemotherapy drugs are on the market but only a handful have proven to be appropriate for fighting mesothelioma. In most cases, doctors treating mesothelioma patients recommend combination therapy - the tandem use of two different chemotherapy drugs. These combination's have been proven to be the most successful in treating the cancer.
All treatment options will be thoroughly discussed with the patient's oncologistspecialist cancer doctor before a decision is made. Patients should provide a full disclosure of their medical history, including details of any prescriptions and over-the-counter medications being taken to ensure treatment is administered with the most appropriate chemotherapeutic agent.
Currently, the most common chemotherapy drugs for mesothelioma include Alimta (the only FDA-approved drug specifically designed for the treatment of mesothelioma), Cisplatin, Carboplatin, Onconase, Gemcitabine, and Navelbine. The medications are usually administered conventionally (by IV or pill form), or may be used in a newer treatment method called heated chemotherapy.
Can Chemotherapy Cure Mesothelioma?
No it can not cure the cancer, currently there is no proven cure for mesothelioma. However, chemotherapy can help control symptoms and shrink tumors and is largely used as a palliative measure to help improve the patient's quality of life. The development of combination treatments has proved successful in achieving longer survival rates and researchers continue to look for new ways to fight this terrible disease.
Bello Kamorudeen is an health worker and author of several mesothelioma articles.For more inforation on mesothelioma treatments visit http://www.mesotheliomacorner.blospot.com
Mesothelioma and the Potential Accessibility of Tumors
Mesothelioma and the Potential Accessibility of Tumors
ch_client = "articlealley";
ch_type = "mpu";
ch_width = 675;
ch_height = 250;
ch_color_title = "006699";
ch_color_site_link = '006699';
ch_noborders = 1;
ch_vertical ="premium";
ch_sid = "590x250_Article_New_1st";
var d = document.getElementsByTagName('span');
ch_queries = [];
for(var x = 0; x
ch_client = "articlealley";
ch_type = "mpu";
ch_width = 675;
ch_height = 250;
ch_color_title = "006699";
ch_color_site_link = '006699';
ch_noborders = 1;
ch_vertical ="premium";
ch_sid = "590x250_Article_New_1st";
var d = document.getElementsByTagName('span');
ch_queries = [];
for(var x = 0; x
Mean Durations of Asbestos Exposure and Chest Abnormalities
Mean Durations of Asbestos Exposure and Chest Abnormalities
One interesting study is called, "Radiological abnormalities among sheet-metal workers in the construction industry in the United States and Canada : relationship to asbestos exposure" - INIST Diffusion - 2, Allée du Parc de Brabois F-54514 Vandoeuvre-lès-Nancy Cedex. Here is an excerpt: "Abstract - We investigated the possible adverse health effects to sheet-metal workers who had past exposure to asbestos. A cross- sectional medical examination of 1330 workers was conducted during 1986 and 1987 in seven clities in the United States and Canada. A total of 1016 workers had been employed for at least 35 y in the industry, and the mean duration from onset of asbestos exposure was 39.5 y (SD=7.41 y). Chest x-ray abnormalities were found in more than half of the group. Pleural fibrosis, the most frequently found abnormality, was present in 47.0% of the cases and was the only abnormality found in 27.8% of cases; parenchymal interstitial fibrosis, found in 33.1% of cases, was the only abnormality found in 16.2% of cases."
Another interesting study is called, "Cancer Mortality Rate Among Workers in the Asbestos Industry of the Urals" by Kogan, F M, Guselnikova, N A, Gulevskaya, M R. Here is an excerpt: "Based on a twenty year study of the mortality rate of workers in the mining of asbestos, it was found that the death rate was higher than among the rest of the population with reference to cancer of the lungs, stomach, intestines and cervix. A higher incidence of cancer was noted in the age group over 50; the mortality of women working with asbestos was found to be lower than the men in these areas, but considerably higher than among the female population. It is believed that a program of medical awareness should be instituted in work areas where people are employed in the mining, processing and use of asbestos, and that the achievement of low levels of dust in these areas would be a major factor in the lowering of cancer incidence of industrial workers."
Another interesting study is called, "The Evaluation Of Airborne Asbestos Fibres Using A Scanning Electron Microscope" By S. T. Beckett - Here is an excerpt: "Abstract - Asbestos fibres sampled on Nuclepore filters can be directly examined by scanning electron microscope in much greater detail than is possible using the conventional optical microscope/membrane filter technique. Results obtained by the two methods for fibres 5 in length were in good agreement. The new technique could facilitate the development of automatic counting methods for asbestos fibres."
Another interesting study is called, "Malignant vascular tumours of the pleura in "asbestos" workers and endothelial differentiation in malignant Mesothelioma" by R L Attanoosa, S K Suvarnab, E Rheadc, M Stephensc, T J Lockee, M N Sheppardd, F D Pooleyf, A R Gibbsa - Thorax 2000;55:860-863. Here is an excerpt: "Abstract - BACKGROUND Three cases of diffuse malignant vascular tumours of the pleura are described which mimicked malignant mesothelioma clinically and pathologically (so called "pseudomesothelioma"). All had occupational histories of exposure to asbestos. The relationship of these tumours to mesothelioma and asbestos exposure is discussed.
METHODS To examine the histogenetic relationship between mesothelioma and these three tumours an immunohistochemical analysis of vascular marker (CD31, CD34, and Von Willebrand factor) expression was undertaken in 92 cases of pleural mesothelioma, in addition to these three tumours. Electron microscopic fibre analysis of lung tissue was performed on each of the three cases to assess asbestos fibre content.
RESULTS Diffuse pleural epithelioid haemangioendotheliomas may closely resemble malignant mesothelioma clinically and pathologically but, of the 92 pleural mesotheliomas tested, none showed expression of CD31, CD34, and Von Willebrand factor. Although all three cases had claimed exposure to asbestos, ferruginous bodies typical of asbestos were only seen by light microscopy in case 2, and only in this subject was the asbestos fibre content raised in comparison with the range seen in a non-exposed background population. The latent period in the pleural epithelioid haemangioendotheliomas ranged from 18 to 60 years.
CONCLUSIONS Endothelial differentiation does not appear to occur in mesothelioma and therefore should be clearly separated from it. No definite association between pleural epithelioid haemangioendothelioma and exposure to asbestos can be made from this small series but further investigation is warranted."
We all owe a debt of gratitude to these fine researchers for their important work. If you found any of these excerpts helpful, please read the studies in their entirety.
Monty Wrobleski is the author of this article, for more information please click on the following links:
Depuy ASR Recall
Depuy ASR Recall
Mesothelioma Lawyer
One interesting study is called, "Radiological abnormalities among sheet-metal workers in the construction industry in the United States and Canada : relationship to asbestos exposure" - INIST Diffusion - 2, Allée du Parc de Brabois F-54514 Vandoeuvre-lès-Nancy Cedex. Here is an excerpt: "Abstract - We investigated the possible adverse health effects to sheet-metal workers who had past exposure to asbestos. A cross- sectional medical examination of 1330 workers was conducted during 1986 and 1987 in seven clities in the United States and Canada. A total of 1016 workers had been employed for at least 35 y in the industry, and the mean duration from onset of asbestos exposure was 39.5 y (SD=7.41 y). Chest x-ray abnormalities were found in more than half of the group. Pleural fibrosis, the most frequently found abnormality, was present in 47.0% of the cases and was the only abnormality found in 27.8% of cases; parenchymal interstitial fibrosis, found in 33.1% of cases, was the only abnormality found in 16.2% of cases."
Another interesting study is called, "Cancer Mortality Rate Among Workers in the Asbestos Industry of the Urals" by Kogan, F M, Guselnikova, N A, Gulevskaya, M R. Here is an excerpt: "Based on a twenty year study of the mortality rate of workers in the mining of asbestos, it was found that the death rate was higher than among the rest of the population with reference to cancer of the lungs, stomach, intestines and cervix. A higher incidence of cancer was noted in the age group over 50; the mortality of women working with asbestos was found to be lower than the men in these areas, but considerably higher than among the female population. It is believed that a program of medical awareness should be instituted in work areas where people are employed in the mining, processing and use of asbestos, and that the achievement of low levels of dust in these areas would be a major factor in the lowering of cancer incidence of industrial workers."
Another interesting study is called, "The Evaluation Of Airborne Asbestos Fibres Using A Scanning Electron Microscope" By S. T. Beckett - Here is an excerpt: "Abstract - Asbestos fibres sampled on Nuclepore filters can be directly examined by scanning electron microscope in much greater detail than is possible using the conventional optical microscope/membrane filter technique. Results obtained by the two methods for fibres 5 in length were in good agreement. The new technique could facilitate the development of automatic counting methods for asbestos fibres."
Another interesting study is called, "Malignant vascular tumours of the pleura in "asbestos" workers and endothelial differentiation in malignant Mesothelioma" by R L Attanoosa, S K Suvarnab, E Rheadc, M Stephensc, T J Lockee, M N Sheppardd, F D Pooleyf, A R Gibbsa - Thorax 2000;55:860-863. Here is an excerpt: "Abstract - BACKGROUND Three cases of diffuse malignant vascular tumours of the pleura are described which mimicked malignant mesothelioma clinically and pathologically (so called "pseudomesothelioma"). All had occupational histories of exposure to asbestos. The relationship of these tumours to mesothelioma and asbestos exposure is discussed.
METHODS To examine the histogenetic relationship between mesothelioma and these three tumours an immunohistochemical analysis of vascular marker (CD31, CD34, and Von Willebrand factor) expression was undertaken in 92 cases of pleural mesothelioma, in addition to these three tumours. Electron microscopic fibre analysis of lung tissue was performed on each of the three cases to assess asbestos fibre content.
RESULTS Diffuse pleural epithelioid haemangioendotheliomas may closely resemble malignant mesothelioma clinically and pathologically but, of the 92 pleural mesotheliomas tested, none showed expression of CD31, CD34, and Von Willebrand factor. Although all three cases had claimed exposure to asbestos, ferruginous bodies typical of asbestos were only seen by light microscopy in case 2, and only in this subject was the asbestos fibre content raised in comparison with the range seen in a non-exposed background population. The latent period in the pleural epithelioid haemangioendotheliomas ranged from 18 to 60 years.
CONCLUSIONS Endothelial differentiation does not appear to occur in mesothelioma and therefore should be clearly separated from it. No definite association between pleural epithelioid haemangioendothelioma and exposure to asbestos can be made from this small series but further investigation is warranted."
We all owe a debt of gratitude to these fine researchers for their important work. If you found any of these excerpts helpful, please read the studies in their entirety.
Monty Wrobleski is the author of this article, for more information please click on the following links:
Depuy ASR Recall
Depuy ASR Recall
Mesothelioma Lawyer
Good Information on Diffuse Pleural Malignant Mesothelioma
Good Information on Diffuse Pleural Malignant Mesothelioma
One of the most events of this pleural mesothelioma is a an effect of a person being exposed freely to asbestos. Most of the time it is assorted under pleural mesothelioma which is a cancerous tumor on the outmost component of the lungs. The pleura is a slight membrane that embraces the lungs. symptoms of asbestos vulnerability can be envisioned on the person involved when the outward covering of the lungs which is the pleura is sick. Getting this form of a cancerous disease can not be envisioned day in and day out because the symptoms can be found even 20 years after he inhaled asbestosit can be found after a lengthy time from 10 to 40 years after vulnerability to asbestos. Some known and common features of an affected person include coughing away blood, swelling of face and skin, fatigue, unhoped-for weight loss, and trouble to breath. Most doctors are not so informed with this disease so it is tough for them to name a person carrying it. This is really aggressive and distributes very speedy. Exceptional known measures and diagnosing are of Computed Tomography (CT scan), Position Emission Tomography, Magnetic Resonance Imaging (MRI), and some other laboratory trials. One of the most impressive modes to obtain an evidence for the illness is over incision on the chest to ensure the pleura, this procedure is addressed as thoractomy. Most of the time, thoractomy is the most painless fashion to obtain diffuse malignant pleural mesothelioma. Pleural mesothelioma is compiled of some points. It needs pots of method actings in order to find out which point a person goes to. Finding Out a good physician on this illness is serious because simply a small list of them bears a splendid cognition on this illness. Precise categorization and arranging can result to the correct processes and measures in healing the disease or at least to sustain a patient?s lifetime. Latter phases can be serious for therapy than early levels. Previous patients are cogent evidences that this illness can be acquired out over stage 1 surgical operation. Notwithstanding, on that point is exclusively a slender number who held up for individuals who are in the worst phases. Chemotherapy does not look to amend the stats until now. It will be long before an efficient cure will be revealed and there are yet live takes on the medications and therapeutics for this illness.
If you would like more info on Diffuse pleural malignant mesothelioma, visit: http://www.financeliberty.com. If you are looking for specialists? Go to Diffuse pleural malignant mesothelioma,
Related Articles -
pleural, mesothelioma, cancer, illness, disease, cancerous, physicians, doctors, doctor,
Email this Article to a Friend!
Receive Articles like this one direct to your email box!Subscribe for free today!
One of the most events of this pleural mesothelioma is a an effect of a person being exposed freely to asbestos. Most of the time it is assorted under pleural mesothelioma which is a cancerous tumor on the outmost component of the lungs. The pleura is a slight membrane that embraces the lungs. symptoms of asbestos vulnerability can be envisioned on the person involved when the outward covering of the lungs which is the pleura is sick. Getting this form of a cancerous disease can not be envisioned day in and day out because the symptoms can be found even 20 years after he inhaled asbestosit can be found after a lengthy time from 10 to 40 years after vulnerability to asbestos. Some known and common features of an affected person include coughing away blood, swelling of face and skin, fatigue, unhoped-for weight loss, and trouble to breath. Most doctors are not so informed with this disease so it is tough for them to name a person carrying it. This is really aggressive and distributes very speedy. Exceptional known measures and diagnosing are of Computed Tomography (CT scan), Position Emission Tomography, Magnetic Resonance Imaging (MRI), and some other laboratory trials. One of the most impressive modes to obtain an evidence for the illness is over incision on the chest to ensure the pleura, this procedure is addressed as thoractomy. Most of the time, thoractomy is the most painless fashion to obtain diffuse malignant pleural mesothelioma. Pleural mesothelioma is compiled of some points. It needs pots of method actings in order to find out which point a person goes to. Finding Out a good physician on this illness is serious because simply a small list of them bears a splendid cognition on this illness. Precise categorization and arranging can result to the correct processes and measures in healing the disease or at least to sustain a patient?s lifetime. Latter phases can be serious for therapy than early levels. Previous patients are cogent evidences that this illness can be acquired out over stage 1 surgical operation. Notwithstanding, on that point is exclusively a slender number who held up for individuals who are in the worst phases. Chemotherapy does not look to amend the stats until now. It will be long before an efficient cure will be revealed and there are yet live takes on the medications and therapeutics for this illness.
If you would like more info on Diffuse pleural malignant mesothelioma, visit: http://www.financeliberty.com. If you are looking for specialists? Go to Diffuse pleural malignant mesothelioma,
Related Articles -
pleural, mesothelioma, cancer, illness, disease, cancerous, physicians, doctors, doctor,
Email this Article to a Friend!
Receive Articles like this one direct to your email box!Subscribe for free today!
Getting a Handle on Acid Reflux Cures
Getting a Handle on Acid Reflux Cures
If you are constantly bombarded with painful stabbing pain in your chest with a bile sting in your mouth, then you might be interested in finding out some acid reflux cures. A number of things can bring about such condition.
The list may include certain positions you take immediately after eating such as lying down. A preference for food items that are enriched with fatty acids, carbonated soft drinks, chocolate and even some veggies and fruits like oranges, tomatoes along with dairy products may trigger this condition to happen.
Such a condition is almost often associated with one or a combination of these symptoms. The symptoms include heartburn that is often persistent and uncomfortably burning, some may also manifest swelling in the esophagus, nausea, earaches, cough that is often persistent and renders a transformation in ones voice, and that painful stab in the chest that often radiates all over the upper extremities.
Free Yourself From the Discomfort
So if you want to free yourself from these discomforts, getting a bit of knowledge on some acid reflux cures would be of great help. Most are often practical and can be done even without any professional help. Some of these practical tips are given below:
• Trying alternating positions - some instances of attacks seem to be in association with how one position their body. Refraining from immediately lying down after a heavy full meal will help block a possible attack. Elevating ones head when you are sleeping especially at night has also been observed to significantly reduce attacks in the middle of the night. Preferring the left side body position has also been associated with reducing attacks in the evening.
• Say no to food triggers - a list of food that can stimulate the opening of the esophageal sphincter is available online and avoiding those will spare you from so much discomfort. Let go of your binge or try with all your might to resist temptation. For it not to be so harsh on your part, little reduction on a regular basis will eventually help you eliminate those food items that can start a sudden attack.
• Home remedies - succumbing to some easy to prepare home remedies will also spare one from so much pain and discomfort, although they are not a permanent solution.
Your best option is to follow an acid reflux diet plan or even consult with your doctor before doing anything. Acid reflux cures usually result in a change in lifestyle.
Our site will help you whether you are looking for information on an symptoms of acid reflux or just information on the types of foods that cause acid reflux. Visit our site today for more information. By T. Houser
If you are constantly bombarded with painful stabbing pain in your chest with a bile sting in your mouth, then you might be interested in finding out some acid reflux cures. A number of things can bring about such condition.
The list may include certain positions you take immediately after eating such as lying down. A preference for food items that are enriched with fatty acids, carbonated soft drinks, chocolate and even some veggies and fruits like oranges, tomatoes along with dairy products may trigger this condition to happen.
Such a condition is almost often associated with one or a combination of these symptoms. The symptoms include heartburn that is often persistent and uncomfortably burning, some may also manifest swelling in the esophagus, nausea, earaches, cough that is often persistent and renders a transformation in ones voice, and that painful stab in the chest that often radiates all over the upper extremities.
Free Yourself From the Discomfort
So if you want to free yourself from these discomforts, getting a bit of knowledge on some acid reflux cures would be of great help. Most are often practical and can be done even without any professional help. Some of these practical tips are given below:
• Trying alternating positions - some instances of attacks seem to be in association with how one position their body. Refraining from immediately lying down after a heavy full meal will help block a possible attack. Elevating ones head when you are sleeping especially at night has also been observed to significantly reduce attacks in the middle of the night. Preferring the left side body position has also been associated with reducing attacks in the evening.
• Say no to food triggers - a list of food that can stimulate the opening of the esophageal sphincter is available online and avoiding those will spare you from so much discomfort. Let go of your binge or try with all your might to resist temptation. For it not to be so harsh on your part, little reduction on a regular basis will eventually help you eliminate those food items that can start a sudden attack.
• Home remedies - succumbing to some easy to prepare home remedies will also spare one from so much pain and discomfort, although they are not a permanent solution.
Your best option is to follow an acid reflux diet plan or even consult with your doctor before doing anything. Acid reflux cures usually result in a change in lifestyle.
Our site will help you whether you are looking for information on an symptoms of acid reflux or just information on the types of foods that cause acid reflux. Visit our site today for more information. By T. Houser
Selasa, 26 Juli 2011
Value in Distinguishing Mesotheliomas from other Tumors
>
Another interesting study titled "Pleurectomy / decortication in the setting of multimodality treatment of diffuse malignant pleural mesothelioma." Do Rusch VW.
Memorial Sloan-Kettering Cancer Center, Department of Surgery and Cornell University Medical College, New York, NY 10021st Semin Thorac Cardiovasc Surg. . October 1997, 9 (4) :367-72 Here's an excerpt: "Abstract - Pleurectomy / decortication is frequently performed operation for patients with diffuse malignant pleural mesothelioma (DMPM) has a low surgical mortality (manje. than 5%), but is associated with significant risk of local recurrence. to date, intensive adjuvant chemotherapy or radiation is not reduced this risk. Despite these disappointing results, pleurectomy / decortication May still be the best treatment option for some patients, particularly those with early disease whose condition excludes pneumonectomy. role of pleurectomy / decortication combined with newer treatment strategies such as neoadjuvant therapy or gene therapy warrants investigation ."
Another interesting study titled "The presence of simian virus 40 sequences in mesothelioma and mesothelial cells is associated with high levels of vascular endothelial growth factor." Do Cacciotti P, Strizzi L, Vianale G, L Iaccheri, Libener R, Porta C, Tognoni M, Gaudino G, Mutti L - Am J Respir Cell Mol Biol. 2002 February, 26 (2) :189-93.
Here is an excerpt: "Abstract - The aim of this study was to assess whether the presence of simian virus-40 (SV40) is associated with an increased release of vascular endothelial growth factor (VEGF) in human malignant mesothelioma (MM) cells Mi. Studied nine cell lines derived from pleural effusion (PE) in patients with MM, and three different cultures of normal human mesothelial cells (NHMC) derived from pleural fluid of patients with congestive heart failure. NHMC were transfected with full length SV40 (NHMC-FL) or large T antigen (Tag NHMC ) DNA. high levels of VEGF were detected in the conditioned media, each of the two MM cells that tested positive for SV40 by PCR amplification and Southern hybridization and dried Tag transcript by reverse transcription-polymerase chain reaction (RT-PCR) and immunoprecipitation. we also found that NHMC-FL released high amounts of VEGF. Conditioned medium from SV40-positive MM cells and from FL-NHMC increased proliferation of human umbilical vein cells (HUVEC) and this effect was partially reversed the addition of specific antibodies against VEGF blocker. These results provide the first evidence that SV40 can cause VEGF release in SV40-positive MM cells and that the whole viral genome is required for this effect ."
We all owe debt of gratitude to these fine researchers for their work. If you find any of these statements of support, read the study in its entirety.
Langganan:
Komentar (Atom)